Patisiran
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Alnylam PharmaceuticalsPhase 3Dormant
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Transthyretin Amyloidosis (ATTR) With Cardiomyopathy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Aln-Ttrsc02 Alnylam Pharmaceuticals | Phase 3 | B |
Ntla-2001 Intellia Therapeutics | Phase 3 | B |
Same molecule, other indications
Patisiran is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →